TRIMEDYNE STOCK HEATS UP WITH SIDE-FIRING LASER CLEARANCE FOR BPH, GAINS 156% IN MARCH; O-T-C INDEX SLIDES 2.6% FOR SECOND STRAIGHT MONTHLY DECLINE
This article was originally published in The Gray Sheet
Executive Summary
Trimedyne's receipt of 510(k) clearance for use of its side-firing laser to treat benign prostatic hyperplasia warmed up investor interest in the company in March, sending its stock ahead 156%, from 3-1/8 to 8. News of the clearance, the first for a laser to treat BPH, rekindled enthusiasm about sales and earnings prospects at the Irvine, California-based firm.